Scott Gale, executive director for Halliburton Labs, has died, leaving behind a legacy of innovation, collaboration, and curiosity. Photo via Rice University

Houston energy and innovation leader Scott Gale died on September 24 after a years-long fight with cancer. He was 40 years old.

Gale was the inaugural executive director for Halliburton Labs, which launched in 2020. Prior to that role, he lead global strategy initiatives for Halliburton. A Brigham Young University graduate, he received his MBA from Rice University in 2019, where he co-founded the Jones Student Association for Executives. After his graduation, he served on the the Rice Business Alumni Association Board and the Energy Advisory Board for the Rice Alliance Clean Energy Accelerator.

"Scott made an impact with his incredible kindness, energy, and talent," Dale Winger, managing director at Halliburton Labs, tells InnovationMap. "Scott was passionate about his family, his friends, his community, and his work. He provided incredible creativity and drive to bring Halliburton Labs to life within Halliburton, and despite a terrible cancer diagnosis, Scott continued to collaborate and build connections that launched the inaugural Houston Energy and Climate Startup Week. Work and play were always fun with Scott. His generosity and dedication to strengthen the Houston innovation ecosystem will be missed, yet his legacy endures.”

Gale was also a voice actor and the co-host of two podcasts: Rice University's Owl Have You Know Podcast, which shares experiences of Rice's business community, and the Curiosity podcast, which explored optimism and curiosity with guests and co-host Brad Rossacci.

"A rebellious optimist at his core, Scott believed we need a biased toward action, a mission focused belief system, and a healthy dose of rebellion for good measure," Rossacci, who serves as creative director at Accenture, says. "Carving his own path in the universe, Scott discovered his life’s work and unceasingly committed himself to helping humanity deepen their curiosity, building connective tissue across society, and advancing the future of energy on the shoulders of the giants who came before him. Ultimately, fulfilling his infinite ambitions and creating an echo that will reverberate in the cosmos for eternity."

One month ago, he stepped away from his role at Halliburton Labs, sharing his cancer journey in a message shared on LinkedIn. In the post, he encouraged his whole community to "go out and live a life that echoes," and ended with "onward," something Gale regularly imparted when he spoke on progress within energy and innovation.

Earlier this month during the Houston Energy and Climate Startup Week, which Gale was instrumental in creating but unable to attend due to the progression of his illness, the Energy Tech Nexus awarded its Nexus Community Award to Gale, and his father, Andrew Gale, accepted the award on his behalf.

"He is very focused on the community in Houston and the tech industry," Andrew Gale said about his son when accepting the award, "he feels so honored to be given the opportunity to be able to have an influence."

In addition to his father and his mother, JoAnna, Scott is survived by his wife of 18 years, Nicole, and their four children, as well as his seven siblings — Siara, Shanna, Spencer, Seth, Shalya, Sam, and Shane. In honor of his brother, Sam launched a GoFundMe campaign for his nieces and nephew's education, and donations are currently being accepted.

In his obituary, his family shared something Scott regularly said as he battled his cancer with countless hospital visits and experimental treatments: “I’m not a doctor, but I’m pretty sure if you die, the cancer dies at the same time. That’s not a loss. That’s a draw.”

Earlier this year, he joined the Houston Innovators Podcast to discuss Houston Energy and Climate Startup Week and call for collaboration within the ecosystem.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”